Editas medicine stock price.

Transcript : Editas Medicine, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 10:00 AM Sep. 11: CI Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating Aug. 03: MTComplete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Editas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

Find the latest Editas Medicine, Inc. (8EM.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Real-time Price Updates for Editas Medicine (EDIT-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreEditas Medicine saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 16,770,000 shares, an increase of 2.1% from the previous total of 16,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...Editas Medicine (EDIT 0.86%) and Bluebird Bio (BLUE 2.64%) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%.Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.

Editas Medicine (NASDAQ: EDIT) $10.49 (3.7%) $0.37 Price as of November 22, 2023, 4:00 p.m. ET Key Data Points Current Price $10.49 Daily Change (3.7%) $0.37 Day's …

Price is a widely used stock evaluation measure. Find the latest Price for Editas Medicine (EDIT) ... Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates 11/03/23-7:45AM EST Zacks

Editas Medicine (NASDAQ: EDIT) $10.49 (3.7%) $0.37 Price as of November 22, 2023, 4:00 p.m. ET Key Data Points Current Price $10.49 Daily Change (3.7%) $0.37 Day's …What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...Editas Medicine stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics Motley Fool - Mon Oct 2, 9:00AM CDT . The better of the pair should be able to beat Bluebird Bio. EDIT: 10.77 (+2.28%) CRSP: 68.65 (+2.88%) Why Editas …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Over the last month the Editas Medicine, Inc. (NASDAQ:EDIT) has been much stronger than before, rebounding by 72%.Meanwhile over the last three years the …

Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The sale of Editas stock could be related to the biotech's upcoming announcement of clinical data. ... Price as of November 29, 2023, 4:00 p.m. ET ... Keith Speights owns shares of Editas Medicine ...Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 62.28% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...

Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.

Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11 · ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo ...Editas Medicine (NASDAQ: EDIT) $10.49 (3.7%) $0.37 Price as of November 22, 2023, 4:00 p.m. ET Key Data Points Current Price $10.49 Daily Change (3.7%) $0.37 Day's …Nov 30, 2023 · A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.DraftKings (NASDAQ:DKNG) was upgraded to Buy from Neutral at MoffettNathanson, with its price target raised by $6.00 to $37.00. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to …The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.--Editas Medicine, Inc., a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per ...Gene editing stocks rallied Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite recent selloff. Read more here.

Editas Medicine stock declined 13% over a 5-day trading period ending 1/21/2021, compared to broader market (S&P500) rise of 1.3%. A change of -13% or more over 5 trading days is a 6% likelihood ...

Jun 15, 2023 · CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.

Stock price history for Editas Medicine (EDIT). Highest end of day price: $90.58 USD on 2021-01-08. Lowest end of day price: $6.36 USD on 2023-04-12. Stock ...Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) …Apr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... Editas Medicine (EDIT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.57 per share a year ago. These figures ...Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ...Editas Medicine, Inc. (EDIT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Editas Medicine, Inc. | Nasdaq: EDIT | Nasdaq …The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Editas Medicine, Intellia Therapeutics, and Vertex …Mar 10, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ... What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ... 24 Okt 2023 ... Stock Price Forecast. According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts ...Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...For example, Editas Medicine (EDIT 11.37%) and Exact Sciences (EXAS 7.07%) fell by 66.5% and 36.4% respectively over the course of 2022. Since the change in the calendar year, Editas stock has ...

The genome editing company's revenue was $6.3 million. That's rather impressive for a clinical-stage biotech, and well up from the roughly $379,000 Editas posted in the second quarter of 2021. Net ...Editas Medicine Inc stock price live 10.42, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or …Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...Editas Medicine is a CRISPR company based out of Cambridge, Massachusetts, working "to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines " At the ...Instagram:https://instagram. how to buy hex coinplug power inc stock priceacrua nsxjim cramer news What happened. Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday ...Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. noco noco incotcmkts tcnnf With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ... when did 401k plans start Recent reports have lowered Editas Medicine’s price target from $36.00 to $30.00 and raised it from $13.00 to $15.00. Editas Medicine’s stock opened at $6.71 and has a 50-day moving average of $8.70 and a 200-day moving average of $9.86. The company’s market capitalization is $462.79 million, and it has a PE ratio of -2.09 and a …The genome editing company's revenue was $6.3 million. That's rather impressive for a clinical-stage biotech, and well up from the roughly $379,000 Editas posted in the second quarter of 2021. Net ...